|

Physical Activity and Exercise During Early Treatment Phases for Childhood Acute Lymphoblastic Leukaemia to Protect Against Muscle Loss and Improve Frailty Outcomes

RECRUITINGN/ASponsored by Murdoch Childrens Research Institute
Actively Recruiting
PhaseN/A
SponsorMurdoch Childrens Research Institute
Started2026-02-24
Est. completion2028-07-17
Eligibility
Age5 Years – 17 Years
Healthy vol.Accepted

Summary

This is a small trial testing out a new approach before doing a bigger study. Researchers are observing a group of children/adolescents (ages 5-17) with acute lymphoblastic leukemia (ALL) and testing a physical activity and exercise program on a group of them who after 5 weeks of treatment show signs of weakness or frailty. Kids who are NOT losing muscle aren't part of the exercise trial - they're just monitored over time to see how they do. The goal: To see if an exercise program helps kids who are getting weaker from acute lymphoblastic leukemia treatment build back/maintain their strength, compared to kids who don't do the extra intervention. The study will also look at if this way of measuring muscle weakness works well for kids with cancer.

Eligibility

Age: 5 Years – 17 YearsHealthy volunteers accepted
Inclusion Criteria:

* Aged 5-17 years at the time of consent
* New diagnosis of acute lymphoblastic leukaemia \<7 days
* Is planned to receive management for their cancer treatment at the trial site for the duration of the trial period
* Has a legally acceptable representative capable of understanding the informed consent document in English and providing consent on the participant's behalf
* Have a family electronic device that can be linked with the tool to be used (Fitbit)

Exclusion Criteria:

* none

Conditions3

Acute Lymphoblastic LeukemiaCancerSarcopenia

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.